Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
Public ClinicalTrials.gov record NCT01722045. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 4, open-label, single arm, multicenter, clinical study in patients with neovascular AMD designed to evaluate the efficacy and safety of Intravitreal Aflibercept Injection (IAI) administered over 2 years , and to provide clinical information from the first year in the trial evaluating the adverse effects, if any, on the corneal endothelium following administration of IAI.
Study identification
- NCT ID
- NCT01722045
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 154 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2012 (Type not available)
- Primary completion
- Sep 2015 (Actual)
- Completion
- Sep 2015 (Actual)
- Last update posted
- Dec 22, 2017
2012 – 2015
United States locations
- U.S. sites
- 49
- U.S. states
- 25
- U.S. cities
- 49
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Beverly Hills | California | — | — |
| Not listed | Oakland | California | — | — |
| Not listed | Palm Desert | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | Santa Ana | California | — | — |
| Not listed | Westlake Village | California | — | — |
| Not listed | Colorado Springs | Colorado | — | — |
| Not listed | Golden | Colorado | — | — |
| Not listed | Boynton Beach | Florida | — | — |
| Not listed | Fort Lauderdale | Florida | — | — |
| Not listed | Fort Myers | Florida | — | — |
| Not listed | Pensacola | Florida | — | — |
| Not listed | Plantation | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Winter Haven | Florida | — | — |
| Not listed | Augusta | Georgia | — | — |
| Not listed | Oak Park | Illinois | — | — |
| Not listed | New Albany | Indiana | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | Jackson | Michigan | — | — |
| Not listed | Lincoln | Nebraska | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Portsmouth | New Hampshire | — | — |
| Not listed | Bloomfield | New Jersey | — | — |
| Not listed | Lawrenceville | New Jersey | — | — |
| Not listed | Northfield | New Jersey | — | — |
| Not listed | Teaneck | New Jersey | — | — |
| Not listed | Rochester | New York | — | — |
| Not listed | Asheville | North Carolina | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Salem | Oregon | — | — |
| Not listed | Kingston | Pennsylvania | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | Florence | South Carolina | — | — |
| Not listed | Ladson | South Carolina | — | — |
| Not listed | West Columbia | South Carolina | — | — |
| Not listed | Rapid City | South Dakota | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01722045, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 22, 2017 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01722045 live on ClinicalTrials.gov.